StemCyte Receives IND Clearance Of Mononuclear Stem Cells In Spinal Cord Injury Clinical Trials

Creative Commons License Source:  Pech Frantisek , no changes made.
Advertisement img

On December 14, 2018, the U.S. Food and Drug Administration (FDA), approved StemCyte’s Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury.

Founded in 1997, headquartered in Baldwin Park, Greater Los Angeles Area, StemCyte’s rich history started with a mission of dedication to helping the world’s physicians save more lives by providing high quality, safe, and effective stem cell transplantation and therapy to all patients in need.

With locations in the US, India, and Taiwan, StemCyte has supplied over 2,200 cord blood units for a variety of life-threatening diseases to over 350 leading worldwide transplant centers. StemCyte is actively involved in the development of stem cell therapies. StemCyte has also been chosen by the US Department of Health and Human Services to help establish a Public National Cord Blood Inventory.

Featured Partners

MC001 is a regenerative cell therapy drug, which is designed to regenerate neurons in patients who suffered chronic, severe, stable spinal cord injury. MC001 has already been shown to be efficacious, safe and well tolerated in a Phase II trial conducted by Dr. Wise Young of Rutger’s University in Kunming, China. Starting in early 2019, within the United States, this Phase II study will be performed at a number of clinical centers in New Jersey.

“This is a great achievement by the StemCyte team. As a leading regenerative cell therapy company, the success of the MC001 will put StemCyte in the central position in the emerging stem cell application markets,” … “FDA’s announcement marks StemCyte having successfully reached the major milestone of the advancement of our regenerative cell therapy program. With our highly experienced expert investigators, we plan to bring this new innovative treatment option in early 2019 to this highly unmet medical need in patient populations with chronic, severe, stable spinal cord injury.” – Jonas Wang, StemCyte’s CEO and Chairman